A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination
| Autor: | Douglas B. Lowrie, Rong Qu, Xiao-Yong Fan, Jin-chuan Xu, Zhen-yan Chen, Ling Zhang, Jianping Chen, Wenrong Yao, Juan Wu, Yong Liu, Heng Yang, Zhidong Hu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Dose optimum
COVID-19 Vaccines medicine.medical_treatment Dose-Response Relationship Immunologic Biology Antibodies Viral Protein vaccine Immunoglobulin G Article QS21 Quillaja SaponariaMolina fraction 21 Immunogenicity Vaccine Adjuvants Immunologic Virology medicine Animals Humans Neutralizing antibody Adjuvants Vaccine Antigens Viral Adjuvant Mice Inbred BALB C SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 COVID-19 Coronavirus disease 2019 IgG Immunoglobulin G SARS-CoV-2 Immunogenicity MPL 3-O-desacyl–monophosphoryl lipid A COVID-19 Saponins QS21 Antibodies Neutralizing Recombinant Proteins Vaccination Drug Combinations HEK293 Cells Lipid A Immunization Immunology Antibody Formation Spike Glycoprotein Coronavirus Vaccines Subunit biology.protein Female Antibody |
| Zdroj: | Virology |
| ISSN: | 1096-0341 0042-6822 |
| Popis: | Background Recombinant protein subunit vaccination is considered to be a safe, fast and reliable technique when combating emerging and re-emerging diseases such as coronavirus disease 2019 (COVID-19). Typically, such subunit vaccines require the addition of adjuvants to attain adequate immunogenicity. AS01, which contains adjuvants MPL and saponin QS21, is a liposome-based vaccine adjuvant system that is one of the leading candidates. However, the adjuvant effect of AS01 in COVID-19 vaccines is not well described yet. Methods In this study, we utilized a mixture of AS01 as the adjuvant for an S1 protein-based COVID-19 vaccine. Results The adjuvanted vaccine induced robust immunoglobulin G (IgG) binding antibody and virus-neutralizing antibody responses. Importantly, two doses induced similar levels of IgG binding antibody and neutralizing antibody responses compared with three doses and the antibody responses weakened only slightly over time up to six weeks after immunization. Conclusion These results suggested that two doses may be enough for a clinical vaccine strategy design using MPL & QS21 adjuvanted recombinant protein, especially in consideration of the limited production capacity of COVID-19 vaccine in a public health emergency. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect